# Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

> **NCT05391490** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University College, London** · enrollment: 12 (estimated)

## Conditions studied

- Blood Cancer

## Interventions

- **GENETIC:** KCAT19 T cells

## Key facts

- **NCT ID:** NCT05391490
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-10
- **Primary completion:** 2024-11
- **Final completion:** 2034-11
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05391490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05391490, "Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05391490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*